Advertisement

Drugs

, Volume 79, Issue 1, pp 43–61 | Cite as

Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice

  • Carla GreenbaumEmail author
  • Dana VanBueckenEmail author
  • Sandra Lord
Review Article
  • 108 Downloads

Abstract

The novel understanding that the presence of multiple islet autoantibodies, indicating islet autoimmunity, inevitably leads to type 1 diabetes mellitus (T1DM) has necessitated the development of a new staging classification system for the condition. Coupled with an improved understanding of the disease course, the realization that T1DM appears to be more heterogeneous than previously thought has led to unique opportunities to develop more targeted therapies that may be applied even before the onset of dysglycemia or symptoms. To date, several therapies have been trialed to delay or halt disease progression in both presymptomatic and clinical T1DM, each demonstrating varying degrees of effectiveness, toxicity, and utility. Key research supports the eventual implementation of immunotherapy in autoimmune diabetes, potentially calling for a paradigm shift among care providers. It will likely be necessary to develop new approaches to trial design and to address potential barriers to progress before an effective treatment for the disease may be achieved.

Notes

Compliance with Ethical Standards

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Conflict of interest

Carla Greenbaum has received personal fees from Lilly, Bristol-Myers Squibb, and Pfizer and grants and personal fees from NovoNordisk and Janssen. Sandra Lord and Dana VanBuecken declare that they have no conflict of interest.

Human and animal rights and informed consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

References

  1. 1.
    Walsh D, McWilliams D. Mechanisms, impact and management of pain in rheumatoid arthritis. Nat Rev Rheumatol. 2014;10:581–92.PubMedGoogle Scholar
  2. 2.
  3. 3.
    group D. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med, 1993. 329(14): p. 977-986.Google Scholar
  4. 4.
    Group, E.o.D.I.a.C.E.R., Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow- up of the Diabetes Control and Complications Trial cohort. Diabetes Care, 1999. 22(1): p. 99-111.Google Scholar
  5. 5.
    Secrest AM, Washington RE, Orchard TJ. Mortality in Type 1 DIabetes, in Diabetes in America, 3rd Edition. 2016, National Institutes of Health, p. 1–16.Google Scholar
  6. 6.
    Miller KM, et al. Current state of Type 1 diabetes treatment in the US: updated data from the T1D exchange clinic registry. Diabetes Care. 2015;38(6):971–8.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986;314(21):1360–8.PubMedGoogle Scholar
  8. 8.
    Sosenko JM, et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care. 2008;31(11):2188–92.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Greenbaum CJ, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes. 2012;61(8):2066–73.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Krogvold L, et al. Function of isolated pancreatic islets from patients at onset of Type 1 diabetes: insulin secretion can be restored after some days in a nondiabetogenic environment in vitro: results from the DiViD Study. Diabetes. 2015;64(7):2506–12.PubMedGoogle Scholar
  11. 11.
    Keenan HA, et al. Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 2010;59(11):2846–53.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Atkinson M, Gianani R. The pancreas in human type 1 diabetes: providing new answers to age-old questions. Curr Opin Endocrinol Diabetes Obes. 2009;16:279–85.PubMedGoogle Scholar
  13. 13.
    Pugliese A, Yang M, Kusmarteva I. The juvenile diabetes research foundation network for pancreatic organ donors with diabetes (nPOD) program: goals, operational model and emerging findings. Pediatr Diabetes. 2014;15(1):1–9.PubMedGoogle Scholar
  14. 14.
    Davis AK, et al. Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care. 2015;38(3):476–81.PubMedGoogle Scholar
  15. 15.
    Steffes MW, et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26(3):832–6.PubMedGoogle Scholar
  16. 16.
    Lachin JM, et al. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes. 2014;63(2):739–48.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Hirshberg B, et al. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care. 2003;26(12):3288–95.PubMedGoogle Scholar
  18. 18.
    Leitão C, et al. Restoration of hypoglycemia awareness after islet transplantation. Diabetes Care. 2008;31(11):2113–5.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Mahon JL, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS. TrialNet Natural History Committee, Type 1 Diabetes TrialNet Study Group. The trialnet natural history study of the development of type 1 diabetes: objectives, design, and initial results. Pediatr Diabetes. 2009;10(2):97–104.PubMedGoogle Scholar
  20. 20.
    Redondo MJ, et al. Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia. 2001;44:354–62.PubMedGoogle Scholar
  21. 21.
    Noble JA, Erlich HA. Genetics of type 1 diabetes. Cold Spring Harb Perspect Med. 2012;2(1):a007732.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet. 1996;59(5):1134.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Pociot F, et al. Genetics of type 1 diabetes: What’s next? Diabetes. 2010;59:1561–71.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Pugliese A, et al. HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype protects autoantibody-positive relatives from type 1 diabetes throughout the stages of disease progression. Diabetes. 2016;65(4):1109–19.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Jerram S, Leslie RD. The genetic architecture of type 1 diabetes. Genes. 2017;8(8):209.PubMedCentralGoogle Scholar
  26. 26.
    Ikegami H, et al. Genetics of type 1 diabetes: similarities and differences between Asian and Caucasian populations. Ann N Y Acad Sci. 2006;1079:51–9.PubMedGoogle Scholar
  27. 27.
    Hagopian WA, et al. Glutamiate decarboxylase, insulin, and islet cell antibodies and HLA typing to detect diabetes in a general population based study of Swedish children. J Clin Invest. 1995;95(4):1505–11.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Rewers M, et al. Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). Diabetologia. 1996;39(7):807–12.PubMedGoogle Scholar
  29. 29.
    Winkler C, et al. A strategy for combining minor genetic susceptibility genes to improve prediction of disease in type 1 diabetes. Genes Immun. 2012;13:549–55.PubMedGoogle Scholar
  30. 30.
    Achenbach P, et al. Natural history of type 1 diabetes. Diabetes. 2005;54(Suppl 2):S25–31.PubMedGoogle Scholar
  31. 31.
    Wherrett DK, et al. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care. 2015;38(10):1975–85.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med. 2009;360(16):1646–54.PubMedGoogle Scholar
  33. 33.
    Insel RA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964–74.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Steck AK, et al. Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). Diabetes Care. 2015;38(5):808–13.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Achenbach P, et al. Characteristics of rapid vs slow progression to type 1 diabetes in mulitple islet autoantibody-positive children. Diabetologia. 2013;56:1615–22.PubMedGoogle Scholar
  36. 36.
    Ziegler AG, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. J Am Med Assoc. 2013;309(23):2473–9.Google Scholar
  37. 37.
    Orban T, et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care. 2009;32(12):2269–74.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Parikka V, Nanto-Salonen K, Saarinen M, Simell T, Ilonen J, Hyöty H, Veijola R, Knip M, Simell O. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia. 2012;55(7):1926–36.PubMedGoogle Scholar
  39. 39.
    Krischer JP, et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia. 2015;58(5):980–7.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Bosi E, et al. Impact of age and antibody type on progression from single to multiple autoantibodies in type 1 diabetes relatives. J Clin Endocrinol Metab. 2017;102(8):2881–6.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Krischer J, Type 1 Diabetes TrialNet Study Group. The use of intermediate endpoints in the design of type 1 diabetes prevention trials. Diabetologia. 2013;56(9):1919–24.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Krischer JP, et al. The influence of type 1 diabetes genetic susceptibility regions, age, sex, and family history to the progression from multiple autoantibodies to type 1 diabetes: a TEDDY Study Report. Diabetes, 2017.Google Scholar
  43. 43.
    Winkler C, et al. Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies. Pediatr Diabetes. 2012;13(4):308–13.PubMedGoogle Scholar
  44. 44.
    Elding Larsson H, et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care. 2011;34(11):2347–52.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Triolo T, et al. Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset. Diabetes Care. 2009;32:769–73.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Haller MJ, Atkinson MA, Schatz D. Type 1 diabetes mellitus: etiology, presentation, and management. Pediatr Clin North Am. 2005;52(6):1553–78.PubMedGoogle Scholar
  47. 47.
    American Diabetes Association, I. American Diabetes Association Standards of Medical Care in Diabetes2017. Diabetes Care. 2017;40((Supplement 1)):S1–134.Google Scholar
  48. 48.
    Rewers A, et al. Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: the Search for Diabetes in Youth Study. Pediatrics. 2008;121:e1258–66.PubMedGoogle Scholar
  49. 49.
    Hagopian WA, et al. The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. Pediatr Diabetes. 2011;12(8):733–43.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Neu A, et al. Ketoacidosis at diabetes onset is still frequent in children and adolescents: a multicenter analysis of 14, 664 patients from 106 institutions. Diabetes Care. 2009;32:1647–8.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Barker J, et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care. 2004;27(6):1399–404.PubMedGoogle Scholar
  52. 52.
    Insel RA, Dunne JL, Ziegler AG. General population screening for type 1 diabetes: has its time come? Curr Opin Endocrinol Diabetes Obes. 2015;22(4):270–6.PubMedGoogle Scholar
  53. 53.
    Raab J, et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open. 2016;6(5):e011144.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Zhao Z, et al. A miltiplex assay combining insulin, GAD, IA-2, and transglutaminase autoantibodies to facilitate screening for pre-type 1 diabetes and celiac disease. J Immunol Methods. 2016;430:28–32.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Prevention, C.f.D.C.a, National diabetes statistics report, 2017. 2017, Centers for Disease Control and Prevention, U.S. Dept. of Health and Human Services.: Atlanta, GA.Google Scholar
  56. 56.
    EURODIAB ACE Study Group. Variation and trends in incidence of childhood diabetes in Europe. Lancet. 2000;355(9207):873–6.Google Scholar
  57. 57.
    Veijola R, et al. HLA-DQB1-defined genetic susceptibility, beta cell autoimmunity, and metabolic characteristics in familial and nonfamilial insulin-dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group. Vol. 98. 1996. 2489–95.Google Scholar
  58. 58.
    Diabetes, B.D.C.f. ASK Research Program/Autoimmunity Screening for Kids. 2018 3/16/2018; https://www.askhealth.org/. Accessed 28 Dec 2018.
  59. 59.
    GPPAD: Global platform for the prevention of autoimmune diabetes. [cited 2018 March 28]; Available from: https://www.gppad.org/en/. Accessed 28 Dec 2018.
  60. 60.
    Sosenko J, et al. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care. 2013;36(9):2615–20.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Type 1 Diabetes TrialNet. Long-term investigative follow-up in TrialNet (LIFT). Type 1 Diabetes: Stage 3. https://www.trialnet.org/our-research/long-term-follow-up. Accessed 28 Dec 2018.
  62. 62.
    Ziegler AG, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473–9.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Chimel R, et al. Progression from single to multiple islet autoantibodies ofter occurs soon after seroconversion: Implications for early screening. Diabetologia. 2015;58:411–3.Google Scholar
  64. 64.
    Harjutsalo V, Podar T, Tuomilehto J. Cumulative incidence of type 1 diabetes in 10,168 siblings of Finnish young-onset type 1 diabetic patients. Diabetes. 2005;54(2):563–9.PubMedGoogle Scholar
  65. 65.
    Hagopian WA, et al. TEDDY–the environmental determinants of diabetes in the young: an observational clinical trial. Ann N Y Acad Sci. 2006;1079:320–6.PubMedGoogle Scholar
  66. 66.
    Mrena S, et al. Models for predicting type 1 diabetes in siblings of affected children. Diabetes Care. 2006;29(3):662–7.PubMedGoogle Scholar
  67. 67.
    Steck A, Johnson K, Barriga K. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: Diabetes Autoimmunity Study in the Young. Diabetes Care. 2011;34:1397–9.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Bougneres PF, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med. 1988;318(11):663–70.PubMedGoogle Scholar
  69. 69.
    Vanbuecken D, Lord S, Greenbaum C. Changing the course of disease in type 1 diabetes, in Endotext. South Dartmouth: MDText.com Inc.; 2015.Google Scholar
  70. 70.
    Ridker P, Everett B, Thuren T. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.PubMedGoogle Scholar
  71. 71.
    Moran A, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013;381(9881):1905–15.PubMedGoogle Scholar
  72. 72.
    Mastrandrea L, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care. 2009;32(7):1244–9.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Clinicaltrials.gov, A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes. Last updated March 1, 2018. Accessed March 20, 2018.https://clinicaltrials.gov/ct2/show/NCT03298542.
  74. 74.
    Clinicaltrials.gov, Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes (T1GER); NCT02846545. 2017.Google Scholar
  75. 75.
    ClinicalTrials.gov, Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D (USTID). Last updated May 25, 2016. Accessed March 20, 2018.https://clinicaltrials.gov/ct2/show/NCT02117765.
  76. 76.
    Hundhausen C, et al. Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. Sci Transl Med. 2016;8(356):356ra119.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Clinicaltrials.gov. Tocilizumab (TCZ) in new-onset type 1 diabetes. https://clinicaltrials.gov/ct2/show/NCT02293837?term=tocilizumab&cond=Type+1+Diabetes&rank=1. Last updated 26 Nov 2018, Accessed 20 Mar 2018.
  78. 78.
    Lisowska-Myjak B, Pachecka J, Kaczynska B, Miszkurka G, Kadziela K. Serum protease inhibitor concentrations and total antitrypsin activity in diabetic and non-diabetic children during adolescence. Acta Diabetol. 2006;43(4):88–92.PubMedGoogle Scholar
  79. 79.
    Gottlieb PA, Alkanani A. Michels AW α1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes. J Clin Endocrinol Metab. 2014;99:E1418–26.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Clinicaltrials.gov, Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus. Last updated June 9, 2016. https://clinicaltrials.gov/ct2/show/NCT01304537. Accessed 20 Mar 2018.
  81. 81.
    Clinicaltrials.gov, The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes. Last updated March 24, 2017. https://clinicaltrials.gov/ct2/show/NCT01319331. Accessed 20 Mar 2018.
  82. 82.
    Louvet C, Szot G, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA. 2008;105(48):18895–900.PubMedGoogle Scholar
  83. 83.
    Clinicaltrials.gov, Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus. Last updated June 21, 2017. https://clinicaltrials.gov/ct2/show/NCT01781975. Accessed 20 Mar 2018.
  84. 84.
    Gitelman S. Imatinib (Gleevec) in New-Onset Type 1 Diabetes—Background and Results. Diabetes, 2017. 66 (suppl 1). https://professional.diabetes.org/webcast/imatinib-gleevec-new-onset-type-1-diabetes%E2%80%94background-and-results. Accessed 23 Mar 2018.
  85. 85.
    Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, Brough HA, Phippard D, Basting M, Feeney M, Turcanu V, Sever ML, Gomez Lorenzo M, Plaut M, Lack G, LEAP Study Team. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372(9):803–13.PubMedGoogle Scholar
  86. 86.
    Pescovitz MD, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361(22):2143–52.PubMedGoogle Scholar
  87. 87.
    Ostrov DA, Alkanani A, McDaniel KA, Case S, Baschal EE, Pyle L, Ellis S, Pöllinger B, Seidl KJ, Shah VN, Garg SK, Atkinson MA, Gottlieb PA, Michels AW. Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. J Clin Invest. 2018;128(5):1888–902.PubMedPubMedCentralGoogle Scholar
  88. 88.
    Clinicaltrials.gov, Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes. Last updated April 6, 2016. https://clinicaltrials.gov/ct2/show/NCT01883804. Accessed 23 Mar 2018.
  89. 89.
    Clinicaltrials.gov, Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes. Last updated March 2, 2018. https://clinicaltrials.gov/ct2/show/NCT03396484. Accessed 20 Mar 2018.
  90. 90.
    Orban T, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):412–9.PubMedPubMedCentralGoogle Scholar
  91. 91.
    Clinicaltrials.gov. CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1; NCT01773707. 2017.Google Scholar
  92. 92.
    Herold KC, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1692–8.PubMedGoogle Scholar
  93. 93.
    Herold KC, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62(11):3766–74.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Clinicaltrials.gov. Teplizumab for prevention of type 1 diabetes in relatives "at-risk". https://clinicaltrials.gov/ct2/show/NCT01030861?term=teplizumab&cond=type+1+diabetes&rank=5. Last updated 9 July 2018, Accessed 26 Dec 2018.
  95. 95.
    Rigby MR, et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013;1(4):284–94.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Rigby MR, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015;125(8):3285–96.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Haller MJ, et al. Anti-thymocyte globulin/G-CSF treatment preserves beta cell function in patients with established type 1 diabetes. J Clin Invest. 2015;125(1):448–55.PubMedGoogle Scholar
  98. 98.
    Haller MJ, et al. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves beta-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care. 2018;41(9):1917–25.PubMedGoogle Scholar
  99. 99.
    Long SA, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes. 2012;61(9):2340–8.PubMedPubMedCentralGoogle Scholar
  100. 100.
    Clinicaltrials.gov, Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes (DIABIL-2). Last updated Nov 9, 2016. https://clinicaltrials.gov/ct2/show/NCT02411253. Accessed 20 Mar 2016.
  101. 101.
    Bluestone J, Buckner J, Fitch M, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7(315):315ra189.PubMedPubMedCentralGoogle Scholar
  102. 102.
    clinicaltrials.gov, T1DM Immunotherapy Using CD4 + CD127lo/-CD25 + Polyclonal Tregs (Treg). Last updated May 20, 2016. https://clinicaltrials.gov/ct2/show/NCT01210664. Accessed 20 Mar 2018.
  103. 103.
    Clinicaltrials.gov, T1DM Immunotherapy Using Polyclonal Tregs + IL-2 (TILT), in. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2017 April 13]. http://clinicaltrials.gov/show/NCT02772679NLM Identifier: NCT02772679.
  104. 104.
    Libman IM, Miller K, DiMeglio LA, et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA. 2015;314(21):2241–50.PubMedGoogle Scholar
  105. 105.
    Clinicaltrials.gov, Autoimmune Diabetes Accelerator Prevention Trial. Last updated Aug 29, 2016. https://clinicaltrials.gov/ct2/show/NCT02881528. Accessed 20 Mar 2018.
  106. 106.
    Kielgast U, Asmar M, Madsbad S, Holst JJ. Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients. J Clin Endocrinol Metab. 2010;95(5):2492–6.PubMedGoogle Scholar
  107. 107.
    Htike Z, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524–36.PubMedGoogle Scholar
  108. 108.
    Zhang J, Tokui Y, Yamagata K, Kozawa J, Sayama K, Iwahashi H, Okita K, Miuchi M, Konya H, Hamaguchi T, Namba M, Shimomura I, Miyagawa JI. Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia. 2007;50(9):1900–9.PubMedGoogle Scholar
  109. 109.
    Rother KI, et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care. 2009;32(12):2251–7.PubMedPubMedCentralGoogle Scholar
  110. 110.
    Clinicaltrials.gov, Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes. Last updated Oct 27, 2017. https://clinicaltrials.gov/ct2/show/NCT02617654. Accessed 20 Mar 2018.
  111. 111.
    Clinicaltrials.gov, A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function. Last updated March 9, 2018. https://clinicaltrials.gov/ct2/show/NCT02443155. Accessed 20 Mar 2018.
  112. 112.
    Clinicaltrials.gov, Incretin-based Therapy in Early Diagnosed Type 1 Diabetes. Last updated Oct 26, 2017. https://clinicaltrials.gov/ct2/show/NCT02908087. Accessed 20 Mar 2018.
  113. 113.
    Clinicaltrials.gov, Incretin-based Therapy in Late Preclinical Type 1 Diabetes. Last updated Oct 26, 2017. https://clinicaltrials.gov/ct2/show/NCT02898506. Accessed 20 Mar 2018.
  114. 114.
    Clinicaltrials.gov, Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults. Last updated Oct 26, 2017. https://clinicaltrials.gov/ct2/show/NCT02611232. Accessed 20 Mar 2018.
  115. 115.
    Rooman I, Lardon J, Bouwens L. Gastrin stimulates β-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes. 2002;51:686–90.PubMedGoogle Scholar
  116. 116.
    Inci F, Atmaca M, Ozturk M, et al. Pantoprazole may improve beta cell function and diabetes mellitus. J Endocrinol Invest. 2014;37(5):449–54.PubMedGoogle Scholar
  117. 117.
    Han N, Oh M, Park SM, et al. The effect of proton pump inhibitors on glycated hemoglobin levels in patients with type 2 diabetes mellitus. Can J Diabetes. 2015;39(1):24–8.PubMedGoogle Scholar
  118. 118.
    Hove KD, Brons C, Færch K, et al. Effects of 12 weeks’ treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. Diabetologia. 2013;56(1):22–30.PubMedGoogle Scholar
  119. 119.
    Wasko MC, McClure CK, Kelsey SF, et al. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia. 2015;58(10):2336–43.PubMedPubMedCentralGoogle Scholar
  120. 120.
    Clinicaltrials.gov, Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus. Last updated Feb 12, 2018. https://clinicaltrials.gov/ct2/show/NCT03428945. Accessed 20 Mar 2018.
  121. 121.
    Nathan DM, Bayless M, Cleary P, for the DCCT/EDIC Research Group, et al. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: advances and contributions. Diabetes. 2013;62:3976–86.PubMedPubMedCentralGoogle Scholar
  122. 122.
    Lachin JM, Genuth S, Cleary P, Nathan DM, for the EDIC Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–9.PubMedGoogle Scholar
  123. 123.
    Group ER. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–67.Google Scholar
  124. 124.
    Knip M, et al. Hydrolyzed infant formula and early beta-cell autoimmunity: a randomized clinical trial. JAMA. 2014;311(22):2279–87.PubMedPubMedCentralGoogle Scholar
  125. 125.
    Knip M, Writing group for teh TRIGR Study Group. Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes. JAMA. 2018;319(1):38–48.PubMedPubMedCentralGoogle Scholar
  126. 126.
    Norris JM, et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA. 2003;290(13):1713–20.PubMedGoogle Scholar
  127. 127.
    Hummel S, Pfluger M, Hummel M. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care. 2011;34(6):1302–5.Google Scholar
  128. 128.
    Gale EA, et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004;363(9413):925–31.PubMedGoogle Scholar
  129. 129.
    Gibson V, Nikolic T, Pearce V, et al. Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model. Clin Exp Immunol. 2015;182(3):251–60.PubMedPubMedCentralGoogle Scholar
  130. 130.
    Ludvigsson J, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med. 2012;366(5):433–42.PubMedGoogle Scholar
  131. 131.
    Wherrett DK, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011;378(9788):319–27.PubMedPubMedCentralGoogle Scholar
  132. 132.
    Ali MA, Liu Y, Arif S, et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Sci Transl Med. 2017;9(402):eaaf7779.Google Scholar
  133. 133.
    Nanto-Salonen K, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet. 2008;372(9651):1746–55.PubMedGoogle Scholar
  134. 134.
    Group, D.P.T.S. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1685–91.Google Scholar
  135. 135.
    Skyler JS, Krischer J, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care. 2005;28(5):1068–76.PubMedGoogle Scholar
  136. 136.
    Skyler J. Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci. 2008;1150:190.PubMedPubMedCentralGoogle Scholar
  137. 137.
    Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study, G., et al. Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2017;318(19):1891–902.Google Scholar
  138. 138.
    Bonifacio E, et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA. 2015;313(15):1541–9.PubMedGoogle Scholar
  139. 139.
    Clinicaltrials.gov, Pre-POINT-Early Study: NCT02547519.Google Scholar
  140. 140.
    Clinicaltrials.gov, Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2018 Nov 26] http://clinicaltrials.gov/show/NCT02580877NLM Identifier: NCT02580877.
  141. 141.
    Clinicaltrials.gov, Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes. Last updated Oct 7, 2016. https://clinicaltrials.gov/ct2/show/NCT00336674. Accessed 20 Mar 2018.
  142. 142.
    Clinicaltrials.gov, Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies. Last updated August 24, 2017. https://clinicaltrials.gov/ct2/show/NCT02387164. Accessed 20 Mar 2018.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Benaroya Research InstituteSeattleUSA

Personalised recommendations